Kornimate/medical-research-clean huggingface dataset:
electrical stimulation of the optic nerve in patients with glaucoma.

Conditions: Glaucoma

Summary: the goal of this observational study is to evaluate electrical stimulation of the optic nerve with the eyetronic nextwave system device as a possible treatment for glaucoma. the main question it aims to answer is: could this therapy be an option to counteract the loss of visual field seen in glaucoma and thus delay the progression of the disease? participants will have approximately 14-18 study visits during 12 months including 10 visits for the electrical stimulation treatment. the treatment involves electrically stimulating the optic nerve by an external approach via the facial skin.

1. during the study visits participants will have: general eye examination (visual acuity check, examination of the front and back of the eye, eye pressure measurement, pupil dilation), visual field (vf) testing, imaging the optic nerve with optical coherence tomography (oct), optic nerve photos. 2. the treatment will include ten sessions during 2 weeks on an outpatient basis in a quiet and dimly lit room with the patient comfortably seated or lying down in a reclining chair. each treatment session will last approximately 60 minutes including the time to determine the treatment settings.

Eligibility criteria:
inclusion criteria: * subjects 18 years or older who have glaucoma * humphrey visual field mean deviation (md) values between - 6 db and -20 db exclusion criteria: * age \< 18 years * implanted electronic devices * metallic artifacts in the head (except dentures) * migraine * epilepsy * brain tumor * pregnancy * breastfeeding patients * uncontrolled intraocular pressure (iop) * iop lowering medication started less than six months before enrollment * any intraocular surgery less than 6 months before enrollment * arterial hypertension without appropriate treatment * acute retinal hemorrhage
evaluation of oral plaque removal utilizing an adjunct enzyme pre-rinse

Conditions: Dental Plaque; Dental Caries

Summary: this study aims to investigate the impact of a bromelain pre-rinse adjunct on oral plaque removal in orthodontic subjects. the study's null hypothesis states that there is no statistically significant difference in visual plaque scores among orthodontic subjects with or without proteolytic enzyme rinse aid.

bromelain, a naturally occurring cysteine protease, from pineapple stalks, is used in food and medical industries and listed on the fda's "generally recognized as safe" (gras) list. in vitro bromelain study demonstrated antibacterial effect on oral pathogens. bromelain was found to prevent biofilm formation by interfering with bacteria-bacteria adhesion and/or adhesion to enamel surface. clinical trials with toothpaste containing bromelain demonstrated improved plaque and gingivitis scores and extrinsic enamel stain removal capabilities. the impact of bromelain application prior to traditional mechanisms of plaque removal have not been clearly evaluated.

Eligibility criteria:
inclusion criteria: * male or female * 10 to 25 years of age * willing to consent to participation * able to follow study instructions * in active orthodontic treatment with fixed orthodontic appliances exclusion criteria: * unwilling/unable to follow study instructions * documented/suspected pineapple allergy * proteolytic enzyme allergy * food dye allergy * smoker

Keywords: proteolytic enzyme plaque removal oral hygiene orthodontic treatment
safety and tolerability study evaluating acr325 in parkinson's disease patients

Conditions: Parkinson's Disease; Tolerability

Summary: the study will evaluate the safety and tolerability of acr325 in parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson"s disease according to the united kingdom parkinson's disease society brain bank diagnostic criteria * levodopa induced dyskinesia exclusion criteria: * previous surgery for parkinson's disease * any current or history of heart condition or increased pro-arrhythmic risk * severe or ongoing unstable medical condition

Keywords: parkinson's disease levodopa dyskinesia acr325
radiation therapy with or without goserelin and cyproterone in treating patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: radiation therapy uses high energy x rays to kill tumor cells. this may be an effective treatment for prostate cancer. androgens can cause the growth of prostate cancer cells. antihormone therapy, such as goserelin and cyproterone, may lessen the amount of androgens made by the body and reduces the amount of androgens available to the body. it is not yet know whether radiation therapy alone is more effective than radiation therapy given together with goserelin and cyproterone in treating patients with prostate cancer. purpose: this randomized phase iii trial is studying radiation therapy to see how well it works compared to giving radiation therapy together with goserelin and cyproterone in treating patients with prostate cancer that is at high risk for metastasis.

objectives: i. evaluate the ability of adjuvant hormone therapy with an lhrh agonist (goserelin depot) to produce an increased disease-free survival and to prolong overall survival when initiated during the first week of radiotherapy in prostatic cancer patients with a high risk of developing metastatic disease. outline: randomized study. arm i: radiotherapy. whole-pelvic irradiation using photons with a recommended energy of at least 10 mv (co60 therapy is acceptable if higher energy unavailable). arm ii: radiotherapy plus 2-drug combination hormonal therapy. whole-pelvic irradiation as in arm i; plus goserelin, zdx, nsc-606864; cyproterone acetate, cptr, nsc-81430. projected accrual: 400 patients will be entered over 5 years. at least 75 patients on each arm should be followed until relapse.

Eligibility criteria:
disease characteristics: histologically proven prostatic adenocarcinoma of the following tnm stages and who grades: t1 or t2 and grade g3 t3 or t4 and any histologic grade no evidence of distant metastases no evidence of positive common iliac or para-aortic lymph nodes confirmed by bone scan, chest x-ray, negative ultrasound or ct of the liver, and ct of the retroperitoneum and/or bipedal lymphangiography extraperitoneal pelvic lymph node biopsy may be either positive or negative provided stage and grade criteria are met patient characteristics: age: under 80 performance status: who 0-2 hematopoietic: not specified hepatic: not specified renal: not specified other: no history of second malignancy except basal cell skin carcinoma prior concurrent therapy: biologic therapy: not specified chemotherapy: no prior chemotherapy for prostate cancer endocrine therapy: no prior hormonal therapy for prostate cancer radiotherapy: no prior radiotherapy for prostate cancer surgery: no prior radical prostatectomy no prior transperitoneal lymph node staging

Keywords: stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer
increasing uptake of ehr-enabled population health outreach strategies to improve diabetes screening

Conditions: Diabetes Mellitus, Type 2; Pre Diabetes

Summary: the study team's central hypothesis is that the parkland diabetes detection program (pddp) screening invitations targeted by race/ethnicity with culturally concordant messaging and tailored by glycemic risk (known pdm vs. unknown glycemic state) plus phone-based navigation of non-responders will be more effective at closing screening gaps than pddp generic screening invitations and usual care, opportunistic screening alone.

the research team will conduct a pragmatic, split cluster randomized controlled trial (clinic=cluster; patient randomization) in 12 community-based primary care clinics in an integrated safety net health system serving a high-risk, racially/ethnically diverse population.

Eligibility criteria:
inclusion criteria: * patient is alive at time of data extraction * age \>= 18 at time of data extraction and \<76 * visit with pcp at parkland clinic in the last 18 months (548 days), where encounter type = virtual visit or encounter type = office visit * patient not included in parkland diabetes registry * preferred language is spanish or english * ethnicity is hispanic or non-hispanic * race is white or black * patient is not pregnant in last 12 months exclusion criteria for study population 1: prediabetes glycemic risk group * last a1c value \<5.7 (normal) * last a1c value \>6.4 (diabetes) * last a1c value = blank (unchecked) * last a1c date occurred within last 12 months from date of export exclusion criteria for study population 2: score-based glycemic risk group * risk score \<9 * last a1c date occurred in last 30 months from date of export * last a1c value was \>5.7 (pdm/dm)

Keywords: diagnostic screening program health system intervention
radiation therapy followed by surgery in treating patients with early-stage breast cancer

Conditions: Breast Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to kill tumor cells. giving ct-guided accelerated radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. purpose: this clinical trial is studying giving radiation therapy followed by surgery to see how well it works in treating patients with early-stage breast cancer.

objectives: * is to investigate the impact of a short fractionated schedule given preoperatively on local control, cosmesis and breast fibrosis. * to further design optimal treatment strategies for individual breast cancer patients treated with breast-conserving therapy (bct) on the basis of biological parameters, including the expression profile of the primary tumor, for both m-rna as for micro-rna, with first, a focus on radiotherapy responsiveness and second, on local recurrence rate, distant metastases and survival. * proteomics will be studied in fine-needle aspiration samples. a classifier can be build (genomic or proteomic or any kind of molecular signature) to identify responders and non-responders * quality of life outline: patients undergo image-guided preoperative accelerated partial-breast irradiation (papbi) 10 times over 12 days (10 x 4 gy) and later in the study 5 times 6 gy. six weeks after completion of image-guided papbi, patients undergo surgery.

Eligibility criteria:
disease characteristics: * diagnosis of unifocal ct1-2 (1-3 cm) pn0 m0 breast cancer * must have undergone a sentinel node procedure prior to irradiation patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: breast cancer invasive breast cancer adenocarcinoma of the breast
ability of a cat food to reduce respiratory symptoms in cat allergic patients

Conditions: Rhinitis, Allergic

Summary: cat allergy is the most common animal allergy, affecting approximately 1 in 5 adults worldwide. the prevalence of allergy to furry animals is increasing, and cat allergy is a major risk factor for the development of asthma and rhinitis. fel-d1 is the major feline allergen, to which 95% of cat allergic people react. all cats produce fel-d1 regardless of breed, age, coat type, sex or weight. fel-d1 is contained primarily in the saliva and sebum of cats. this allergy manifests itself as allergic rhinitis (ar) (sneezing, cold, coughing, conjunctivitis with watering and itching), severe asthma, and irritation and swelling of the skin when scratched. a new approach to managing cat allergies is to neutralize the allergens at the source by feeding domestic cats a diet containing anti-fel-d1 igy antibodies. the purpose of this pilot study is to determine whether feeding domestic cats a food containing an egg product with anti-fel d1 igy (pro plan® livecleat®) induces a reduction of allergic symptoms in their owners.


Eligibility criteria:
inclusion criteria: * uncontrolled allergic rhinitis (with or without treatment) * persistent allergic rhinitis with worsening of symptoms upon exposure to cats * presence of one or two cats in the household, whose diet consists mainly of dry kibble * agreement of the patient to change the food of the cat(s) and to feed it exclusively with the test kibbles during the study. * diagnosis of cat allergy defined by a positive prick test to standardized cat allergen or cat-specific ige. * absence of allergy to pollens emitted in the region during the 4 months following the inclusion date, confirmed by a negative skin test. * person owning an android and/or ios smartphone and having the possibility to connect to the internet (via phone subscription or wifi connection), * person who agrees to install the mask-air application (medical device) on his personal smartphone, * person having read and understood the information note and having signed their participation agreement before any specific procedure of the study. exclusion criteria: * person planning to be away from the cat(s) for more than one week/month in the 4 months following the inclusion visit * patient who has had a new cat in the home for less than one month * patient in regular contact with other animals to which they are allergic * patient with uncontrolled asthma * patient receiving immunotherapy for cat allergies * patient participating or having participated in an allergic rhinitis study within the last 30 days or 5 half-lives of study medication * person who has difficulty understanding or reading the information * person declaring to be under guardianship, curatorship or safeguard of justice.
triceps surae ultrasonographic characteristics in hemiparetic stroke survivors

Conditions: Spastic Foot; Stroke

Summary: this study aims to evaluate, in hemiparetic patients, changes in muscle ultrasound structure about the focal treatment of spasticity with botulinum toxin type a. for this purpose, the analysis of the mean echo intensity will be carried out on ultrasound acquisitions, identifying the possible correlations between the muscle echogenicity, the variations in the pennation angle, and the length of the fascicles. for image processing operations, imagej software was applied.


Eligibility criteria:
inclusion criteria: * unilateral ischaemic or haemorrhagic stroke (documented with clinical examination and neuroradiological findings) * presence of spasticity at lower limb muscles, at least grade 1+ in the modified ashworth scale 3. * age ≥ 18 years exclusion criteria: * inability to walk before stroke * presence of severe cognitive impairment * presence of other musculoskeletal, neurological or cardiopulmonary impairment which can interfere with clinical findings * presence of skin lesions that can contraindicate bont-a treatment * previous surgical myotendinous elongation

Keywords: post-stroke spasticity muscle ultrasound
f 18 t807 tau pet imaging of progressive posterior cortical dysfunction (ind 123119, protocol e)

Conditions: Alzheimer Disease; Progressive Posterior Cortical Dysfunction (PPCD)

Summary: this project will collect quantitative pilot data that will allow the characterization of uptake and binding of 18f-av-1451 (also known as f 18 t807), a novel tau imaging compound, in individuals with progressive posterior cortical dysfunction (ppcd) and logopenic variant primary progressive aphasia (lvppa). the primary goal is to develop tau imaging technique as an antecedent biomarker of cognitive decline. the investigators propose to obtain preliminary data that will support the possibility of detecting cognitive decline in its earliest stages, before the occurrence of dementia.


Eligibility criteria:
inclusion criteria: 1. male or female participants, at least 45 years of age. 2. clinical diagnosis of ppcd. 3. participant is able and willing to undergo testing (mri or ct, pet, radioactive tracer injection, lp; for those unable to undergo an mri, ct will be used to generate regions-of-interest). 4. pre-menopausal women will have a negative urine pregnancy test within 24 hours of t807 drug administration. exclusion criteria: 1. has any condition that, in the investigator's opinion, could increase risk to the participant, limit the participant's ability to tolerate the experimental procedures, or interfere with the collection/analysis of the data (for example, participants with severe chronic back pain might not be able to lie still during the scanning procedures). 2. is deemed likely unable to perform the imaging procedures for any reason. 3. has a high risk for torsades de pointes or is taking medications known to prolong qt interval. 4. has hypersensitivity to f 18 t807 or any of its excipients. 5. contraindications to pet, pet-ct or mr (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate. 6. severe claustrophobia. 7. currently pregnant or breast-feeding. 8. for those electing to undergo the optional lumbar puncture: on anticoagulant of any form prior to lumbar puncture.

Keywords: dementia brain diseases mild cognitive impairment central nervous system diseases neurodegenerative disease
backpack carrying in children with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cystic fibrosis is a hereditary, chronic respiratory illness. cystic fibrosis leads to a progressive decline in lung function. school-aged children with cystic fibrosis experience backpack carrying everyday. backpack carrying induce a restrictive effect responsible for lower lung function. respiratory muscle strength is also impaired. no studies assessed aerobic capacities during children's gait while carrying a backpack. the investigators hypothesized that backpack carrying will induce an acute decline in lung function in children with cystic fibrosis compared to healthy children. investigators also hypothesized that aerobic capacities will be impaired.


Eligibility criteria:
inclusion criteria: * cystic fibrosis * school-aged children (10 to 18) exclusion criteria: * backpack carrying contraindication * acute exacerbation * impossible gait * other respiratory disease (asthma ...)

Keywords: cystic fibrosis backpack carrying respiratory function children
home based computer gaming hand exercise regimen for people with arthritis affecting the hands

Conditions: Rheumatoid Arthritis; Osteoarthritis of Hands

Summary: the purpose of the study is to determine whether a novel computer gaming hand exercise regimen would improve hand function, decrease pain/ stiffness and be feasible in people with rheumatoid arthritis or osteoarthritis affecting the hands.

a novel computer gaming hand exercise regimen has been designed for people with rheumatoid arthritis (ra) or osteo arthritis (oa) affecting the hands. the design allows a broad range of common objects of daily life to be seamlessly transformed into 'therapeutic' input devices by instrumenting with a small motion sense mouse. based on individual abilities and treatment needs, objects are selected to train specific fine/ gross dexterous functions. the object manipulations (therapeutic exercises) are then used to control and play any commercially available computer game, making practice challenging and engaging. the study is of six weeks duration comparing the computer gaming and conventional hand exercises in thirty people diagnosed with ra or oa affecting the hands. the investigators hypothesize that the game based exercises will improve hand function and reduce pain/stiffness and be feasible compared to the conventional hand exercises.a mixed-effect repeated measures analysis of variance will be conducted to test pre to post treatment outcomes. this will be the first study to evaluate the therapeutic effects and feasibility of the computer gaming hand exercise regimen in people with ra or oa.

Eligibility criteria:
inclusion criteria: * men and women * aged between 30-70 years * clinical diagnosis of rheumatoid arthritis or osteoarthritis of hands according to american college of rheumatology criteria * must own a home computer and have basic working knowledge of computers. * present with scores ranging from 0-75 on self-reported hand function ability with the disabilities of arm, shoulder and hand (dash) questionnaire exclusion criteria: * severely deformed finger joints * neurological conditions of dominant side upper limb * trauma in wrist or hand * upper limb surgeries in previous six months * co-existing hand conditions in the dominant hand * problems with vision or hearing * recent changes in drug regimen (disease modifying anti-rheumatic drugs (dmards) or corticosteroids \<3 months) * major diseases of heart or lungs or liver * dash scores 0-75.

Keywords: hand exercises hand function computer based exercises therapeutic gaming
anticoagulant/antiaggregant use and postoperative bleeding risk in patients with bladder tumor and benign prostatic hyperplasia

Conditions: Hematuria; Retention, Urinary; Operative Bleeding; Blood Transfusion Complication

Summary: patients who were using anticoagulant or antiaggregant medications for any reason and underwent transurethral resection of bladder tumor (tur-bt) or transurethral resection of the prostate (turp) or open prostatectomy (op) due to bph will be compared with those who were not using anticoagulant or antiplatelet medication. the rates of postoperative clot retention, presence of hematuria, reoperation due to hematuria, blood transfusion and re-admissions due to hematuria in the first postoperative month will be compared.


Eligibility criteria:
inclusion criteria: * patients undergoing complete endoscopic transurethral tumor resection (tur-bt) for bladder cancer * patients undergoing turp due to benign prostatic hyperplasia * patients undergoing open prostatectomy due to benign prostatic hyperplasia exclusion criteria: * patients who underwent incomplete transurethral tumor resection for bladder cancer * patient who underwent tur biopsy for restaging with no obvious macroscopic tumoral lesion * patients who underwent cystectomy for bladder cancer

Keywords: bladder cancer benign prostatic hyperplasia transurethral resection hematuria